Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No More Sarepta-Like Development, FDA Officials Say

Executive Summary

OND Director Jenkins says Sarepta's Exondys 51 shouldn't be a model, gets an earful from patient advocates.


Related Content

Refining A Controversial Endpoint: Sarepta Banking On Dystrophin Levels For Golodirsen Approval In DMD
Moscicki's Move From FDA To PhRMA About 'Best' Use Of Leadership Skills
Political Appointees Shouldn't Influence Approval Decisions, Califf Says
Accelerated Approval Should Be Less 'Wide Open,' Califf Says
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales
Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Duchenne Group's Presentation Is Milestone For Patient Involvement
Duchenne Muscular Dystrophy: Second Product Isn't The Charm


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts